Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants

Swapna Karkare; Hoa H Le; John J Sheehan; Jennifer Kern Sliwa; Qiaoyi Zhang; Beth Barber

doi:10.18553/jmcp.2020.26.4.568

Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants

J Manag Care Spec Pharm. 2020 Apr;26(4):568-569. doi: 10.18553/jmcp.2020.26.4.568.

Authors

Swapna Karkare¹, Hoa H Le¹, John J Sheehan¹, Jennifer Kern Sliwa¹, Qiaoyi Zhang², Beth Barber¹

Affiliations

¹ Janssen Scientific Affairs Titusville, NJ.
² Janssen Global Services Titusville, NJ.

Abstract

The writing of this letter was supported by Janssen Scientific Affairs. The authors are employees of Janssen Scientific Affairs or Janssen Global Services (Johnson & Johnson).

Publication types

Letter
Comment

MeSH terms

Antidepressive Agents
Cost-Benefit Analysis
Humans
Ketamine*
United States

Substances

Antidepressive Agents
Esketamine
Ketamine